Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Lessons Learned from Large-Scale, First-Tier Clinical Exome Sequencing in a Highly Consanguineous Population.

Monies D, Abouelhoda M, Assoum M, Moghrabi N, Rafiullah R, Almontashiri N, Alowain M, Alzaidan H, Alsayed M, Subhani S, Cupler E, Faden M, Alhashem A, Qari A, Chedrawi A, Aldhalaan H, Kurdi W, Khan S, Rahbeeni Z, Alotaibi M, Goljan E, Elbardisy H, ElKalioby M, Shah Z, Alruwaili H, Jaafar A, Albar R, Akilan A, Tayeb H, Tahir A, Fawzy M, Nasr M, Makki S, Alfaifi A, Akleh H, Yamani S, Bubshait D, Mahnashi M, Basha T, Alsagheir A, Abu Khaled M, Alsaleem K, Almugbel M, Badawi M, Bashiri F, Bohlega S, Sulaiman R, Tous E, Ahmed S, Algoufi T, Al-Mousa H, Alaki E, Alhumaidi S, Althagafi M, Alghamdi H, Alghamdi M, Sahly A, Nahrir S, Al-Ahmari A, Alkuraya H, Almehaidib A, Abanemai M, Alsohaibaini F, Alsaud B, Arnaout R, Abdel-Salam GMH, Aldhekri H, AlKhater S, Alqadi K, Alsabban E, Alshareef T, Awartani K, Banjar H, Alsahan N, Abosoudah I, Alashwal A, Aldekhail W, Alhajjar S, Al-Mayouf S, Alsemari A, Alshuaibi W, Altala S, Altalhi A, Baz S, Hamad M, Abalkhail T, Alenazi B, Alkaff A, Almohareb F, Al Mutairi F, Alsaleh M, Alsonbul A, Alzelaye S, Bahzad S, Manee AB, Jarrad O, Meriki N, Albeirouti B, Alqasmi A, AlBalwi M, Makhseed N, Hassan S, Salih I, Salih MA, Shaheen M, Sermin S, Shahrukh S, Hashmi S, Shawli A, Tajuddin A, Tamim A, Alnahari A, Ghemlas I, Hussein M, Wali S, Murad H, Meyer BF, Alkuraya FS.

Am J Hum Genet. 2019 Jun 6;104(6):1182-1201. doi: 10.1016/j.ajhg.2019.04.011. Epub 2019 May 23.

PMID:
31130284
2.

Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease.

Cappelli B, Volt F, Tozatto-Maio K, Scigliuolo GM, Ferster A, Dupont S, Pinto Simões B, Al-Seraihy A, Aljurf MD, Almohareb F, Belendez C, Matthes S, Dhedin N, Pondarre C, Dalle JH, Bertrand Y, Vannier JP, Kuentz M, Lutz P, Michel G, Rafii H, Neven B, Zecca M, Bader P, Cavazzana M, Labopin M, Locatelli F, Magnani A, Ruggeri A, Rocha V, Bernaudin F, de La Fuente J, Corbacioglu S, Gluckman E.

Haematologica. 2019 Apr 24. pii: haematol.2019.216788. doi: 10.3324/haematol.2019.216788. [Epub ahead of print]

3.

Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group.

Mohammed J, Aljurf M, Althumayri A, Almansour M, Alghamdi A, Hamidieh AA, ElHaddad A, Othman TB, Bazarbachi A, Almohareb F, Alzahrani M, Alkindi SS, Alsharif F, Da'na W, Alhashmi H, Bekadja MA, Al-Shammari SH, El Quessar A, Satti TM, Aljohani N, Rasheed W, Ghavamzadeh A, Chaudhri N, Hashmi SK.

Hematol Oncol Stem Cell Ther. 2019 Jan 11. pii: S1658-3876(18)30122-5. doi: 10.1016/j.hemonc.2018.12.003. [Epub ahead of print] Review.

4.

Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.

Gaafar A, Sheereen A, Almohareb F, Eldali A, Chaudhri N, Mohamed SY, Hanbali A, Shaheen M, Alfraih F, El Fakih R, Iqneibi A, Youniss R, Elhassan T, Hashmi S, Aljurf M, Alhussein K.

Bone Marrow Transplant. 2018 Sep;53(9):1170-1179. doi: 10.1038/s41409-018-0123-7. Epub 2018 Mar 16.

PMID:
29549293
5.

Azacitidine Use for Myeloid Neoplasms.

El Fakih R, Komrokji R, Shaheen M, Almohareb F, Rasheed W, Hassanein M.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e147-e155. doi: 10.1016/j.clml.2018.02.005. Epub 2018 Feb 8. Review.

PMID:
29478947
6.

Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.

Alhashim N, Aljurf M, Hassanein M, Chaudhri N, Hashmi S, El-Gohary G, Alsharif F, Alsermani M, Alhumaid M, Beihany AA, Shaheen M, Hanbali A, Alfraih F, Mohamed S, Alzahrani H, Elhassan T, Eldali A, Rasheed W, Ahmed S, Almohareb F, El Fakih R.

Bone Marrow Transplant. 2018 Jul;53(7):838-843. doi: 10.1038/s41409-018-0093-9. Epub 2018 Jan 25.

PMID:
29371685
7.

Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies.

Chaudhri NA, Aljurf M, Almohareb FI, Alzahrani HA, Bashir Q, Savani B, Gupta V, Hashmi SK.

Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):173-177. doi: 10.1016/j.hemonc.2017.05.016. Epub 2017 Jul 3. Review.

8.

Prevalence and relative proportions of CLL and non-CLL monoclonal B-cell lymphocytosis phenotypes in the Middle Eastern population.

Aljurf M, Rawas F, Alnounou R, Bakshi N, Chaudhri N, Khalil S, Almohareb F, Albitar M.

Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):42-43. doi: 10.1016/j.hemonc.2016.09.003. Epub 2016 Nov 9. No abstract available.

9.

Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].

Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR.

Biol Blood Marrow Transplant. 2017 Mar;23(3):534. doi: 10.1016/j.bbmt.2016.09.021. Epub 2016 Oct 24. No abstract available.

10.

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients.

Alaiya AA, Aljurf M, Shinwari Z, Almohareb F, Malhan H, Alzahrani H, Owaidah T, Fox J, Alsharif F, Mohamed SY, Rasheed W, Aldawsari G, Hanbali A, Ahmed SO, Chaudhri N.

Int J Oncol. 2016 Sep;49(3):913-33. doi: 10.3892/ijo.2016.3618. Epub 2016 Jul 7.

11.

Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.

Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1410-1415. doi: 10.1016/j.bbmt.2016.04.017. Epub 2016 May 3. Erratum in: Biol Blood Marrow Transplant. 2017 Mar;23(3):534.

12.

Donor-derived extramedullary acute promyelocytic leukemia post kidney transplant.

Alhuraiji A, Chebbo W, El-Gohary G, Chaudhri N, Almohareb F, Ibrahim K, Bakshi N, Mohammed S, Abalkhail H, Osman SA.

Ann Hematol. 2015 Mar;94(3):505-7. doi: 10.1007/s00277-014-2200-3. Epub 2014 Sep 9. No abstract available.

PMID:
25217228
13.

Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007.

Ahmed SO, Ghavamzadeh A, Zaidi SZ, Baldomero H, Pasquini MC, Hussain F, Alimoghaddam K, Almohareb F, Ayas M, Hamidieh A, Mahmoud HK, Elhaddad A, Ben Othman T, Abdelkefi A, Sarhan M, Abdel-Rahman F, Adil S, Alkindi S, Bazarbachi A, Benchekroun S, Niederwieser D, Horowitz M, Gratwohl A, El Solh H, Aljurf M.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1352-61. doi: 10.1016/j.bbmt.2011.01.019. Epub 2011 Apr 1.

14.

The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.

Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al-Hussein K, Almohareb F, Chaudhri N, Alsharif F, Al-Zahrani H, Tbakhi A, Aljurf M, Dermime S.

Cancer Res. 2008 Aug 1;68(15):6350-9. doi: 10.1158/0008-5472.CAN-08-0050.

15.

Brain granulocytic sarcoma at the site of previous cerebral hemorrhage in a patient with acute myelogenous leukemia.

Enani MA, Harakati MS, Almohareb FI, Rahman NU, Fawzy EM.

Int J Hematol. 1993 Aug;58(1-2):119-23.

PMID:
8219108

Supplemental Content

Loading ...
Support Center